首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   106553篇
  免费   10759篇
  国内免费   7105篇
耳鼻咽喉   772篇
儿科学   1738篇
妇产科学   1218篇
基础医学   10677篇
口腔科学   2140篇
临床医学   13753篇
内科学   13776篇
皮肤病学   1128篇
神经病学   4589篇
特种医学   3815篇
外国民族医学   38篇
外科学   10473篇
综合类   21309篇
现状与发展   34篇
一般理论   6篇
预防医学   8391篇
眼科学   2537篇
药学   11797篇
  99篇
中国医学   7843篇
肿瘤学   8284篇
  2024年   384篇
  2023年   1572篇
  2022年   3908篇
  2021年   5330篇
  2020年   4343篇
  2019年   3228篇
  2018年   3310篇
  2017年   3551篇
  2016年   3072篇
  2015年   4899篇
  2014年   6009篇
  2013年   6186篇
  2012年   8971篇
  2011年   9704篇
  2010年   7037篇
  2009年   5820篇
  2008年   6833篇
  2007年   6519篇
  2006年   5910篇
  2005年   5417篇
  2004年   3705篇
  2003年   3306篇
  2002年   2623篇
  2001年   1991篇
  2000年   1919篇
  1999年   1714篇
  1998年   950篇
  1997年   1015篇
  1996年   762篇
  1995年   687篇
  1994年   624篇
  1993年   389篇
  1992年   405篇
  1991年   386篇
  1990年   363篇
  1989年   287篇
  1988年   253篇
  1987年   242篇
  1986年   189篇
  1985年   149篇
  1984年   105篇
  1983年   82篇
  1982年   33篇
  1981年   46篇
  1980年   31篇
  1979年   35篇
  1978年   25篇
  1977年   19篇
  1976年   18篇
  1973年   10篇
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
61.
62.
回顾《内经》相关理论,指出痈脓病机关键在于气血凝滞、经络阻塞、脏腑失和,可分期论治。总结《金匮要略》治疗痈脓的方法,认为痈脓应尽早治疗,防邪深入;并根据证情辨证使用清热解毒,活血消散;排除脓毒,泄浊于外等治法。对现代临床仍具实用价值。   相似文献   
63.
Epidermolysis bullosa (EB) is a heritable blistering disorder. We performed a next-generation sequencing-based multigene panel test and successfully predicted 100% of the EB types, including, 36 EB simplex (EBS), 13 junctional EB (JEB), 86 dystrophic EB (DEB), and 3 Kindler EB. Chinese JEB and recessive DEB (RDEB) patients have relatively mild phenotypes; for severe type separately accounts for 45.5% and 23.8%, respectively. We identified 96 novel and 49 recurrent pathogenic variants in 11 genes, although we failed to detect the second mutation in one JEB and five RDEB patients. We identified one novel p.E475K mosaic mutation in the clinically normal mother of one out of 13 EBS patients with KRT5 mutations, one recurrent p.G2034R mosaic mutation, and one novel p.G2043R mosaic mutation in the clinically normal relatives of two out of 19 dominant DEB patients. This study shows that next-generation technology could be an effective tool in diagnosing EB.  相似文献   
64.
目的 探讨中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对三阴性乳腺癌的临床预后影响及与Ki - 67表达的关系。方法 回顾性分析2006年1月 - 2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。NLR最佳临床分界值采用ROC曲线确定,并依此分NLR<2.64组和NLR≥2.64组。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan - Meier和log - rank方法。Ki - 67的表达采用免疫组织化学方法检测。结果 NLR是三阴性乳腺癌的独立预后因素,最佳临界值为2.64。NLR<2.64组术后中位DFS为39.10月,中位OS为52.30月;NLR≥2.64组术后中位DFS为27.35月,中位OS为37.35月。2组术后DFS和OS比较,差异具有统计学意义(P<0.05)。NLR低组伴Ki - 67表达阴性的三阴性患者术后中位DFS和OS生存时间显著高于其他情况。结论 NLR是三阴性乳腺癌的关键影响预后因素,具有重复性强、非侵袭性、方便实用等特性,可用于预测三阴性乳腺癌临床预后。  相似文献   
65.
陈梅  付丛会  沈志强  徐英  贾杰  吴毅 《临床荟萃》2020,35(4):357-361
目的 观察互动式歌唱表演对轻中度阿尔茨海默病(AD)患者抑郁、精神行为症状及运动训练参与率的影响。方法 选取符合入组条件≥60周岁AD患者63例,随机分为研究组(31例)和对照组(32例)。所有受试患者常规药物治疗及常规运动训练,对照组接受被动性音乐治疗,研究组接受以互动歌唱为主的主动性音乐治疗,1次/d,每次1小时,每周训练5天,持续干预6个月。于治疗前、治疗1个月后、治疗3个月后、治疗6个月后分别采用康奈尔痴呆抑郁量表(CSDD)评分、阿尔茨海默病病理行为(BEHAVE AD)评分、参与率进行评估。结果 治疗1个月、3个月后,研究组CSDD评分较治疗前均降低(P<0.05);治疗6个月后,研究组患者CSDD评分较治疗前、治疗1个月、3个月后均显著降低(P<0.05),且与对照组比较差异有统计学意义(P<0.05)。治疗1个月、3个月后,研究组BEHAVE AD评分较治疗前均降低(P<0.05);治疗6个月后,研究组患者BEHAVE AD评分较治疗前、治疗1个月、3个月后均显著降低(P<0.05),且与对照组比较差异有统计学意义(P<0.05)。治疗6个月后,两组运动训练参与率组间比较差异有统计学意义(P<0.05)。结论 互动式歌唱表演可能对改善轻中度AD患者的抑郁和精神行为症状有着积极的疗效,同时对提高受试者运动训练的参与率可能有着更积极的疗效。  相似文献   
66.
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.

Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (35), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass.  相似文献   
67.
建立华细辛和北细辛HPLC特征图谱并结合聚类分析研究2种来源细辛的识别方法;应用网络药理学方法预测细辛潜在抗炎靶点并寻找潜在抗炎成分。对89批细辛药材(12批华细辛和77批北细辛)的数据进行分析确定了11个特征峰,用对照品、紫外光谱和LC-MS指认了11个特征成分。特征峰面积聚类分析显示华细辛和北细辛被分为2类,且利用特征峰面积比值可实现两者区分,当特征峰9(细辛素)/参照峰S(卡枯醇)峰面积比值大于5时为华细辛,小于2时为北细辛。对119种细辛成分进行网络药理学分析的结果表明细辛抗炎作用可能与COX-2,COX-1,iNOS,MAPK14,LAT4H,NR3C1,PPARG和TNF等8个靶点相关,其中COX-2最为关键,与5种特征成分细辛脂素、芝麻脂素、细辛素、甲基丁香酚和黄樟醚均存在相互作用。此外,细辛脂素、芝麻脂素与iNOS,MAPK14也存在相互作用关系,黄樟醚和细辛素可作用于iNOS,COX-1,LAT4H,甲基丁香酚可作用于COX-1,LAT4H。细辛脂素与芝麻脂素均可作用在COX-2,iNOS和MAPK143个靶点上,提示它们是细辛发挥抗炎作用的活性成分;COX-2分子对接结果和COX-2活性实验结果验证了细辛脂素、芝麻脂素可抑制COX-2活性,为细辛抗炎作用活性成分。基于HPLC特征图谱的华细辛和北细辛识别方法简便易行;预测到的细辛抗炎靶点和抗炎成分为完善细辛质量评价体系奠定了基础。  相似文献   
68.
69.
目的 探讨营养风险与腹膜后肿瘤患者住院时间的相关性。方法 采用回顾性研究,选取2012年1月至2018年12月四川大学华西医院血管外科新入院腹膜后肿瘤患者60例,采用营养风险筛查表评估患者营养风险,收集患者体质指数、围术期血红蛋白和白蛋白水平、住院天数、术后恶心呕吐发生情况、术后排气、排便时间和首次进食时间。采用单因素分析比较不同患者住院时间,采用多重线性逐步回归分析患者住院时间的影响因素。结果 纳入的60例腹膜后肿瘤患者中,40例患者(66.7%)术前存在营养风险,52例患者(86.7%)术后存在营养风险;单因素分析显示,患者术前、术后营养风险 (术前P<0.001,术后P=0.043)、术前白蛋白 (P=0.019)、术后血红蛋白 (P=0.019)、术后白蛋白(P=0.025) 水平以及术后恶心呕吐 (P=0.001) 均会影响患者的住院时间;患者住院时间与围术期营养风险筛查工具评分、术后首次进食时间、术后排气时间和排便时间具有相关性,且相关性强(r=0.759~0.770; P<0.01);多因素分析显示术前营养风险是腹膜后肿瘤患者住院时间的重要预测因素(β=0.399)。结论 术前营养风险是腹膜后肿瘤患者住院时间的预测因子。  相似文献   
70.
周洁  毕建朋 《中草药》2019,50(6):1395-1399
目的研究犀角地黄汤加味对败血症导致的炎症和肺损伤的影响,探讨其对核转录因子-κB(NF-κB)信号通路的调控作用。方法制备败血症小鼠模型,测量血清中乳酸脱氢酶(LDH)反映败血症小鼠的器官损伤程度;HE染色观察败血症小鼠肺组织病理学变化;酶联免疫吸附法测定肺组织中细胞因子白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、小鼠巨噬细胞炎症蛋白-2(MIP-2)水平;免疫组化法检测肺组织中粒细胞分化抗原-1(Gr-1)的阳性表达;TUNEL法分析败血症小鼠肺中的TUNEL阳性细胞数量;Western blotting法检测肺组织中NF-κB p65蛋白表达。结果犀角地黄汤加味减轻了败血症小鼠的炎症反应和肺损伤程度,以及嗜中性粒细胞浸润。犀角地黄汤加味显著减少了败血症小鼠肺中的TUNEL阳性细胞数量。结论犀角地黄汤加味可以减轻败血症导致的炎症和肺损伤,可能是通过抑制NF-κB信号通路发挥作用。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号